Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0362 • ACR Convergence 2022
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
Hermine I. Brunner¹, Catharina Lindholm², Ellen Cody¹, Prasad Devarajan¹, Bin Huang¹, Dominic Sinibaldi³, Madhu Ramaswamy³, Jacob Knagenhjelm⁴, Tingting Qiu¹, Frederick Jones⁵, Philip Brohawn³, Raj Tummala³ and Wendy White³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²AstraZeneca, Gothenburg, Sweden, ³AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Gateborg, Sweden, ⁵AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN confers poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We previously showed that…
Abstract Number: 0586 • ACR Convergence 2022
Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse
Shuzo Sato¹, Xian Zhang², Naoki Matsuoka¹, Yuya Sumichika¹, Kenji Saito¹, Shuhei Yoshida¹, Haruki Matsumoto¹, Jumpei Temmoku¹, Yuya Fujita¹, Tomoyuki Asano¹, Hiroshi Watanabe¹ and Kiyoshi Migita¹, ¹Fukushima Medical University, Fukushima, Japan, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Friend leukemia virus integration 1 (Fli-1) belongs to the Ets family of transcription factors and plays an important role in the development of lupus…
Abstract Number: 0645 • ACR Convergence 2022
Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions
Suzanne Shoffner-Beck, Lisa Abernathy-Close, Stephanie Lazar, Amy Hurst, Craig Dobry, Deepika Pandian, Rachael Wasikowski, Kelly Arnold, Johann Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a manifestation of systemic lupus erythematosus (SLE) that can cause significant patient distress and disfiguration secondary to scar. Scarring…
Abstract Number: 0666 • ACR Convergence 2022
HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Seong Hee (Joy) Park¹, Akshay Patel² and Andras Perl³, ¹Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
Abstract Number: 0943 • ACR Convergence 2022
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
Hiba Bilal¹, Amarah Baluch² and Andras Perl³, ¹SUNY Upstate Medical Unviersity, Jamesville, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Women of child-bearing age with underlying rheumatic disease such as systemic lupus erythematous (SLE) with positive anti-phospholipid antibodies (aPL) are at an increased risk…
Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Lucy Marie Carter¹, Zoe Wigston¹, Jack Arnold¹ and Philip Laws², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Cassandra Calabrese¹, Gelareh Atefi², Kristin Evans³, Meghan Moynihan³, Liisa Palmer³ and Sandra Sze-jung Wu⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Hockessin, DE
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…
Abstract Number: 1115 • ACR Convergence 2022
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
Raisa Lomanto Silva¹, Gretchen M Swabe² and Jared W Magnani³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Heart and Vascular Institute, University of Pittsburgh Medical Center; Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with significant morbidity and mortality. Adherence to SLE medications is challenging and estimated as 30-80%…
Abstract Number: 1280 • ACR Convergence 2022
Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
Sidha Sreedharan¹, Geoffrey Littlejohn², Russell Buchanan³, Mandana Nikpour⁴, Eric Morand⁵, Alberta Hoi⁶ and Vera Golder⁷, ¹Monash Health, North Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Austin Health, Heidelberg, Australia, ⁴The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Monash University, Clayton, Australia
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease associated with frequent healthcare interactions. The Chronic Care Model is a widely accepted framework…
Abstract Number: 1379 • ACR Convergence 2022
Association of HLA Alleles with Specific Auto-antibodies in an Ancestrally Diverse Population of Childhood Systemic Lupus Erythematosus (SLE)
Nicholas Gold¹, Fangming Liao¹, JingJing Cao¹, Daniela Dominguez¹, Andrea Knight², Deborah Levy³ and Linda Hiraki⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease capable of affecting multiple organ systems. Genetic variants in the Human Leukocyte Antigen (HLA) are associated…
Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Kassidy Banford¹, hannah Bulgart¹, Shane Bruckner², Stacy Ardoin³, Noah Weisleder² and Wael Jarjour², ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, OH, ³The Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…
Abstract Number: 1594 • ACR Convergence 2022
Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Yiran Jiang¹, Ali Duarte-Garcia², Mike Putman³ and David Gazeley⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³The Medical College of Wisconsin, Milwaukee, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…
Abstract Number: 1708 • ACR Convergence 2022
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
Bahtiyar Toz¹, Jeffrey C wingard², Bruce Volpe² and Betty Diamond², ¹Resident in Queens Hospital Center, Jamaica, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…
Abstract Number: 1764 • ACR Convergence 2022
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
Janet Song¹, Noah Forrest¹, Kathleen Mittendorf², Wei-Qi Wei², Leah Kottyan³, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Abel Kho¹, ¹Feinberg School of Medicine, Chicago, IL, ²Vanderbilt University Medical Center, Nashville, TN, ³Cincinnati Children's Hospital Medical Center, Cincinatti, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a complex and poorly understood etiology and is difficult to diagnose due to its varied presentation across many organ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].